300 related articles for article (PubMed ID: 11426070)
1. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
Martínez E; Blanco JL; Arnaiz JA; Pérez-Cuevas JB; Mocroft A; Cruceta A; Marcos MA; Milinkovic A; García-Viejo MA; Mallolas J; Carné X; Phillips A; Gatell JM
AIDS; 2001 Jul; 15(10):1261-8. PubMed ID: 11426070
[TBL] [Abstract][Full Text] [Related]
2. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
Torti C; Costarelli S; De Silvestri A; Quiros-Roldan E; Lapadula G; Cologni G; Paraninfo G; Castelnuovo F; Puoti M; Carosi G;
Drug Saf; 2007; 30(12):1161-9. PubMed ID: 18035868
[TBL] [Abstract][Full Text] [Related]
3. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
Mbougua JB; Laurent C; Kouanfack C; Bourgeois A; Ciaffi L; Calmy A; Gwet H; Koulla-Shiro S; Ducos J; Mpoudi-Ngolé E; Molinari N; Delaporte E
BMC Public Health; 2010 Mar; 10():105. PubMed ID: 20193053
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
Tseng YT; Yang CJ; Chang SY; Lin SW; Tsai MS; Liu WC; Wu PY; Su YC; Luo YZ; Yang SP; Hung CC; Chang SC
Int J Infect Dis; 2014 Dec; 29():12-7. PubMed ID: 25312984
[TBL] [Abstract][Full Text] [Related]
5. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
Wu PY; Cheng CY; Liu CE; Lee YC; Yang CJ; Tsai MS; Cheng SH; Lin SP; Lin DY; Wang NC; Lee YC; Sun HY; Tang HJ; Hung CC
PLoS One; 2017; 12(2):e0171596. PubMed ID: 28222098
[TBL] [Abstract][Full Text] [Related]
6. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
[TBL] [Abstract][Full Text] [Related]
9. Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa.
Chu KM; Boulle AM; Ford N; Goemaere E; Asselman V; Van Cutsem G
PLoS One; 2010 Feb; 5(2):e9183. PubMed ID: 20174653
[TBL] [Abstract][Full Text] [Related]
10. Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.
McKoy JM; Bennett CL; Scheetz MH; Differding V; Chandler KL; Scarsi KK; Yarnold PR; Sutton S; Palella F; Johnson S; Obadina E; Raisch DW; Parada JP
Drug Saf; 2009; 32(2):147-58. PubMed ID: 19236121
[TBL] [Abstract][Full Text] [Related]
11. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.
Manfredi R; Calza L; Chiodo F
J Acquir Immune Defic Syndr; 2004 Apr; 35(5):492-502. PubMed ID: 15021314
[TBL] [Abstract][Full Text] [Related]
12. Hepatotoxicity in patients prescribed efavirenz or nevirapine.
Brück S; Witte S; Brust J; Schuster D; Mosthaf F; Procaccianti M; Rump JA; Klinker H; Petzold D; Hartmann M
Eur J Med Res; 2008 Jul; 13(7):343-8. PubMed ID: 18700192
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
Jamisse L; Balkus J; Hitti J; Gloyd S; Manuel R; Osman N; Djedje M; Farquhar C
J Acquir Immune Defic Syndr; 2007 Apr; 44(4):371-6. PubMed ID: 17259905
[TBL] [Abstract][Full Text] [Related]
14. Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
Peters PJ; Stringer J; McConnell MS; Kiarie J; Ratanasuwan W; Intalapaporn P; Potter D; Mutsotso W; Zulu I; Borkowf CB; Bolu O; Brooks JT; Weidle PJ
HIV Med; 2010 Nov; 11(10):650-60. PubMed ID: 20659176
[TBL] [Abstract][Full Text] [Related]
15. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS
AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
17. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
Su S; Fairley CK; Sasadeusz J; He J; Wei X; Zeng H; Jing J; Mao L; Chen X; Zhang L
J Med Virol; 2018 Mar; 90(3):518-525. PubMed ID: 29091279
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
[TBL] [Abstract][Full Text] [Related]
19. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
Law WP; Dore GJ; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA
AIDS; 2003 Oct; 17(15):2191-9. PubMed ID: 14523276
[TBL] [Abstract][Full Text] [Related]
20. Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
Snijdewind IJ; Smit C; Godfried MH; Nellen JF; de Wolf F; Boer K; van der Ende ME
J Infect; 2012 Apr; 64(4):409-16. PubMed ID: 22227465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
